MetaVia to Present at the Emerging Growth Conference in December

Rhea-AI Summary

MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced its participation in the upcoming Emerging Growth Conference. The company's President and CEO Hyung Heon Kim, along with CFO Marshall H. Woodworth, will deliver a company update on December 4, 2024, at 4:10 pm ET.

The presentation will include a Q&A session, with attendees able to submit questions either in advance via email or during the event. Interested parties can register online to attend the virtual conference, with additional opportunities available for private management meetings.

News Market Reaction

+1.96%

1 alert

+1.96% News Effect

On the day this news was published, MTVA gained 1.96%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET.

After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to questions@emerginggrowth.com, or ask your questions during the event.

Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-at-the-emerging-growth-conference-in-december-302317541.html

SOURCE MetaVia Inc.

FAQ

When is MetaVia (MTVA) presenting at the Emerging Growth Conference?

MetaVia (MTVA) is presenting at the Emerging Growth Conference on Wednesday, December 4, 2024, at 4:10 pm ET.

How can investors submit questions for MetaVia's (MTVA) presentation?

Investors can submit questions either in advance by emailing questions@emerginggrowth.com or ask them during the live event.

Who will be presenting at the December 2024 Emerging Growth Conference for MetaVia (MTVA)?

President and CEO Hyung Heon Kim and CFO Marshall H. Woodworth will be presenting the company update.

How can investors attend MetaVia's (MTVA) presentation at the Emerging Growth Conference?

Investors can attend by registering for the virtual conference through the provided registration link.